Legend Biotech

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced that a Type II variation application was submitted to EMA for CARVYKTI® based on data from the CARTITUDE-4 study.

Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results. "We are extremely pleased to announce that we have recently raised $762 million in funding. With this substantial capital infusion, we are poised to embark on a critical chapter in our company's growth to advan.

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announces that new and updated data from the CARTITUDE program will be presented at the 2023 ASCO and EHA annual meetings.

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the 2023 RBC Capital Markets Global Healthcare Conference in New York City. Ying Huang, PhD, CEO of Legend Biotech, will participate in a fireside chat on Wednesday, May 17, 2023 at 9:30 a.m. (Eastern Time). About Legend Biotech Legend Bi.

Legend Biotech Announces Participation in Upcoming Investor Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it has agreed to sell 5,468,750 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a price of $64.00 per ADS, in a registered direct offering. The gross proceeds of the offering are expected to be approximately.

Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares

If everyone expects a stock to rise and buys it, eventually someone will be wrong. Legend Biotech's shares are up by quite a bit this year already.

After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech?

Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.

Why Legend Biotech Stock Is Having Its Best Month Yet

Legend reportedly confirmed the leaked results of its multiple myeloma study on Friday, leading LEGN stock to surge. The post Legend Bio Hits Profit-Taking Zone After Reportedly Confirming Key Study Results appeared first on Investor's Business Daily.

Legend Bio Hits Profit-Taking Zone After Reportedly Confirming Key Study Results

Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progression. Stock jumps 20% following the news.

Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study

CRISPR Therapeutics

Madrigal Pharmaceuticals

Vaxcyte

Revolution Medicines

Ventyx Biosciences

Western Alliance Bancorporation

Where is the current bull market? All indications would be that it's in biotech!

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

Legend Biotech Corporation Sponsored ADR (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Legend Biotech Corporation Sponsored ADR (LEGN) Soars 19.6%: Is Further Upside Left in the Stock?

BeiGene

BioMarin Pharmaceutical

Incyte

argenx

Bio-Techne

United Therapeutics

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).

7 Biotech Stocks That Could Cure Your Portfolio Woes

Cancer drug Carvykti had $72 million in sales in the first quarter. Legend's revenues grew by 70% last year.

Why Shares of Legend Biotech Jumped Wednesday

Legend Biotech: Leaked EHA Abstract Shows Outstanding CARTITUDE-4 Results

Legend Biotech is staring down a $9.6 billion opportunity, an analyst said Wednesday as LEGN stock soared on positive cancer test results. The post Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit appeared first on Investor's Business Daily.

Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit

Moderna

We have seen a host of companies such as Moderna Inc and Legend Biotech Corp grow to join the major league of biotech companies. But how do you spot the rookie in the minors ready to make the step up and what are the red flags?

Moderna, Legend Biotech advanced to the major league from the minors. But how do you spot a rookie company ready to move to the ‘show'?

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of Mythili Koneru, M.D., Ph.D. as the Company's Chief Medical Officer. In this role, Dr. Koneru will be responsible for overseeing the Company's clinical development and medical affairs programs. Dr.

Legend Biotech Announces Appointment of Chief Medical Officer

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the formation of a strategic advisory board and the appointments of Michel Vounatsos, former CEO of Biogen Inc., and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, as advisors. Mr. Vounatsos and Dr.

Legend Biotech Establishes Strategic Advisory Board

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its full year 2022 audited financial results. "2022 was a year of significant milestones for Legend Biotech, marked by the regulatory approvals of CARVYKTI® in the U.S., Europe, and Japan.

Legend Biotech Reports Full-Year 2022 Results and Recent Highlights

Roivant Sciences Ltd

Beam Therapeutics

Editas Medicine

Intellia Therapeutics

Ultragenyx Pharmaceutical

While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird myriad therapeutic advancements. For patients, they represent hope for a positive outcome.

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences: Event: Cowen 43rd Annual Healthcare Conference Location: Boston, MA Fireside Chat Date & Time: Tuesday, March 7, 2023 at 9:50am ET Presenter: Ying Huang, Ph.D.

Legend Biotech Announces Participation in Upcoming Investor Conferences

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that it received notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) on February 17, 2023 indicating that the Company has regained compliance with Nasdaq Listing Rules 5250(c)(2).

Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)

Legend Biotech and partner Johnson & Johnson announced positive topline results from the CARTITUDE-4 trial of Carvykti last week. Positive results were expected and the market was not impressed either as no data was mentioned in the press release.

Legend Biotech: CARTITUDE-4 Study A Success

SOMERSET, N.J.--( BUSINESS WIRE )--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that CARTITUDE-4, the Phase 3 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint of showing a statistically significant improvement in progression-free survival (PFS) compared to standard therapy at the study's first pre-specified interim analysis. The study has been unblinded following the recommendation of an independent data monitoring committee.

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

SOMERSET, N.J.--( BUSINESS WIRE )--Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on January 6, 2023 indicating that the Company is not currently in compliance with Nasdaq's Listing Rules (the “Listing Rules”) due to the Company's failure to file an interim balance sheet and income statement as of and for the quarter ended June 30, 2022 on Form 6-K with the Securities and Exchange Commission (“SEC”) . Pursuant to Listing Rule 5250(c)(2), the Company was required to file such Form 6-K no later than six months following the end of the quarter ended June 30, 2022, or December 31, 2022 (the “Due Date”). As of the date of this press release, the Company has not yet filed the required Form 6-K. This delay in filing such Form 6-K has resulted from the Company's planned restatement of its audited financial statements as of and for the years ended December 31, 2021, December 31, 2020 and December 31, 2019 and unaudited interim financial information for the three months ended March 31, 2022, as previously reported by the Company on its Form 6-K dated October 20, 2022.

News for Legend Biotech Stock (LEGN)